Altimmune Inc

3G0

Company Profile

  • Business description

    Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

  • Contact

    910 Clopper Road
    Suite 201S
    GaithersburgMD20878
    USA

    T: +1 240 654-1450

    E: [email protected]

    https://www.altimmune.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    59

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,723.5017.90-0.20%
CAC 407,589.6636.210.48%
DAX 4023,350.55293.171.27%
Dow JONES (US)42,157.8513.81-0.03%
FTSE 1008,774.6517.15-0.20%
HKSE23,530.48292.741.26%
NASDAQ19,424.07122.21-0.63%
Nikkei 22538,403.2385.11-0.22%
NZX 50 Index12,569.0558.27-0.46%
S&P 5005,960.4720.40-0.34%
S&P/ASX 2008,505.5018.20-0.21%
SSE Composite Index3,359.902.21-0.07%

Market Movers